|
John Innes
Centre's impact
Recent speculation in the press has linked the John Innes Centre at
Norwich Research Park in Colney near Norwich with the trials of GM potatoes.
However, the JIC has recently released a calculation of its economic impact
(click here for the report).
According to these figures the JIC generates over £80 million of revenues
and a gross value added of c. £40 million, and is responsible for nearly
1000 jobs.
|
Summary of JIC operating impacts, UK level |
|
Impact type |
Output
£ Million |
Employment
FTEs |
Income
£ Million |
GVA
£ Million |
|
Direct |
£27.5 |
378 |
£16.3 |
£16.3 |
|
Indirect |
£32.1 |
289 |
£7.6 |
£13.7 |
|
Induced |
£23.8 |
283 |
£6.2 |
£12.3 |
|
Total |
£83.4 |
950 |
£30.1 |
£42.4 |
The calculation of final impacts for JIC is
exemplified by work in several areas. In wheat production the JIC has helped
to increase UK wheat production by £75 million per annum. Its contribution
to world wheat production is estimated at £3.4 billion. JIC’s work with
genetically resistant cultivars and fungicide treatments supports global
cereal production. JIC’s work to mitigate major losses in world wheat
production could potentially be as much as £4.3 billion per annum. JIC’s
gene mapping is helping to address world hunger, and can be seen as
leveraging World Bank funding of $5.2 million (£2.6 million) per annum into
organisations such as IRRI (in the Philippines) and CIYMMT (in Mexico
JIC’s work underpins the £38 million annual UK
pea market, with directly attributable sales of £2.9 million per annum.
“Super-Broccoli” research is adding value to consumers in the UK of £0.5
million per annum, and may also contribute to reduced incidence of colon
cancer.
JIC discovered the genetic basis of antibiotic
properties by Streptomyces, a global market now worth $35 billion per
annum. A JIC spin-out company (Novacta Biosystems) has recently received a
£3 million Wellcome Trust grant to work on solutions to Clostridium
difficile and MRSA. If successful, this work could add £194 million to
the UK economy through prevention of avoidable deaths. A new spin-out
company (Procarta Biosystems) is developing a completely new approach to
overcome antibiotic resistance that could have broad application.
|